menu
    • menu
    [{"orgOrder":0,"company":"Aker BioMarine","sponsor":"Aker BioMarine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"||DGAT","graph1":"Neurology","graph2":"Preclinical","graph3":"Aker BioMarine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aker BioMarine \/ Aker BioMarine","highestDevelopmentStatusID":"4","companyTruncated":"Aker BioMarine \/ Aker BioMarine"},{"orgOrder":0,"company":"Aker BioMarine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NORWAY","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Bifidobacterium Lactis","moa":"||Gut microbiome","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Aker BioMarine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Aker BioMarine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aker BioMarine \/ Undisclosed"},{"orgOrder":0,"company":"Aker BioMarine","sponsor":"BioTeSys GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Aker BioMarine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aker BioMarine \/ BioTeSys GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Aker BioMarine \/ BioTeSys GmbH"},{"orgOrder":0,"company":"Aker BioMarine","sponsor":"BioTeSys GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NORWAY","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Krill Oil","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Aker BioMarine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aker BioMarine \/ BioTeSys GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Aker BioMarine \/ BioTeSys GmbH"},{"orgOrder":0,"company":"Aker BioMarine","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NORWAY","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Lysophosphatidylcholine-Rich Oil Extract","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Aker BioMarine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aker BioMarine \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"Aker BioMarine \/ KGK Science"},{"orgOrder":0,"company":"Aker BioMarine","sponsor":"Aker BioMarine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Krill","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Aker BioMarine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aker BioMarine \/ Aker BioMarine","highestDevelopmentStatusID":"1","companyTruncated":"Aker BioMarine \/ Aker BioMarine"}]

    Find Clinical Drug Pipeline Developments & Deals by Aker BioMarine

    Menu

    Aker BioMarine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aker BioMarine

                            Norway arrow
                            The MedTech Conference
                            Not Confirmed

                            Aker BioMarine

                            Norway arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bifidobacterium Lactis,Lactobacillus Gasseri,Lactobacillus Rhamnosus

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioma Probiotics Launches Women’s Gut Health Formula for Natural Weight Loss

                            Details : Bioma Probiotics supports weight loss, balances gut health, and helps women reduce bloating, boost energy, and improve digestion naturally.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            August 05, 2025

                            Lead Product(s) : Bifidobacterium Lactis,Lactobacillus Gasseri,Lactobacillus Rhamnosus

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aker BioMarine

                            Norway arrow
                            The MedTech Conference
                            Not Confirmed

                            Aker BioMarine

                            Norway arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lysophosphatidylcholine-Rich Oil Extract

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : KGK Science

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lysoveta Trial to Assess Cognitive Function in Healthy Adult with Memory Complaints

                            Details : Lysophosphatidylcholine-Rich Oil Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Cognitive Dysfunction.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            June 24, 2025

                            Lead Product(s) : Lysophosphatidylcholine-Rich Oil Extract

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : KGK Science

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aker BioMarine

                            Norway arrow
                            The MedTech Conference
                            Not Confirmed

                            Aker BioMarine

                            Norway arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Krill Oil

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Undisclosed

                            Sponsor : BioTeSys GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigation of Krill Oil in Women with Premenstrual Syndrome

                            Details : Krill Oil is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Premenstrual Syndrome.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            September 05, 2024

                            Lead Product(s) : Krill Oil

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Undisclosed

                            Sponsor : BioTeSys GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aker BioMarine

                            Norway arrow
                            The MedTech Conference
                            Not Confirmed

                            Aker BioMarine

                            Norway arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Krill

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : University of Glasgow

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigating the Effects of Krill Oil and Krill Protein on Post-exercise Muscle Protein Metabolism

                            Details : Krill is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypertrophy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 17, 2023

                            Lead Product(s) : Krill

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : University of Glasgow

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aker BioMarine

                            Norway arrow
                            The MedTech Conference
                            Not Confirmed

                            Aker BioMarine

                            Norway arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omega-3 Fatty Acid

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : BioTeSys GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Uptake of an Omega-3 Oil in Healthy Adults

                            Details : Omega-3 Fatty Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 14, 2022

                            Lead Product(s) : Omega-3 Fatty Acid

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : BioTeSys GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aker BioMarine

                            Norway arrow
                            The MedTech Conference
                            Not Confirmed

                            Aker BioMarine

                            Norway arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl,DHA

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Universite de Sherbrooke Department of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aker BioMarine Enters Into Research Collaboration for Alzheimer’s

                            Details : Université de Sherbrooke in Canada will test if LYSOVETA, Aker BioMarine’s new delivery platform based on LPC-bound EPA/DHA from krill, is more effective in increasing the concentration of DHA in the brain and improving cognition.

                            Product Name : Lysoveta

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 15, 2021

                            Lead Product(s) : Icosapent Ethyl,DHA

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Universite de Sherbrooke Department of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth